newsfilter
← Latest News
GlobeNewswire·

Medexus Completes Enrollment in Phase 4 Clinical Trial of IXINITY® Targeting Label Expansion for Pediatric Hemophilia B Patients

TORONTO and CHICAGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSX:MDP) (OTCQX:MEDXF) today announced that is has completed enrollment in its Phase 4 Clinical Trial of IXINITY®, targeting label expan